The use of preimplantation genetic testing for aneuploidy (PGT-A): a committee opinion

Use of preimplantation genetic testing for aneuploidy (PGT-A) in select patients undergoing in vitro fertilization has been theorized to allow for higher live-birth rates when increased elective single-embryo transfer is used. PGT-A testing reliability has recently come under scrutiny. The impact of mosaicism on testing re- liability and embryo damage from the biopsy still need to be determined.
Published
Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine
Like

Volume 109, Issue 3, Pages 429–436

Authors:

Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology 

Abstract:

The value of preimplantation genetic testing for aneuploidy (PGT-A) as a screening test for in vitro fertilization (IVF) patients has yet to be determined. Several studies demonstrate higher birth rates after aneuploidy testing and elective single-embryo transfer (eSET), suggesting the potential for this testing to decrease the risk of multiple gestations, though these studies have important limitations.


Read the full text here.


Go to the profile of Fertility and Sterility
Fertility and Sterility
Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. 

Comments

Go to the profile of Susan Willman
Susan Willman
9 months ago

Has the ASRM issued any updated statements following  the 2018 Committee Opinion on PGT-A?


Recommended Content